OAG
TPST icon

Orbis Allan Gray’s Tempest Therapeutics TPST Stock Holding History

Orbis Allan Gray’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-902
Closed -$18.9M – 73
2016
Q3 		$18.9M Hold
902
– – 0.13% 53
2016
Q2 		$13.7M Buy
902
+187
+26% +$4.27M 0.1% 58
2016
Q1 		$19.8M Buy
+715
New +$15.1M 0.16% 53

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Orbis Allan Gray's TPST Position: Q4 2016 in Review

Orbis Allan Gray sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 902 shares — an estimated $18.9M sold.

Orbis Allan Gray first reported a position in TPST in Q1 2016 and held it in 3 quarters. The position peaked at $19.8M in Q1 2016. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

  • Orbis Allan Gray reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Orbis Allan Gray sold 902 Tempest Therapeutics shares in Q4 2016, an estimated $18.9M.
  • Orbis Allan Gray first reported a position in Tempest Therapeutics in Q1 2016 and held it in 3 quarters.
  • Orbis Allan Gray's Tempest Therapeutics position peaked at $19.8M in Q1 2016.
  • 84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on Orbis Allan Gray's 13F filing for Q4 2016, filed 14 Feb 2017.